Skip to main content

Table 1 Baseline Demographics of Patients

From: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

  MF-DPI 400 μg QD PM
(n = 611)
MF-DPI 200 μg BID
(n = 622)
Mean age, y 50.9 50.2
Patients by age, n (%)   
   12 to <18 y 21 (3) 22 (4)
   18 to <65 y 444 (73) 465 (75)
   ≥65 y 146 (24) 135 (22)
Sex   
   Women/men 338/273 357/265
Race   
   White/nonwhite 607/4 615/7
Mean body weight, kg 77.3 76.7
  n = 599 n = 614
Mean duration of SAR, y 17.2 19.2
  n = 238 n = 235
Mean duration of PAR, y 19.7 20.9
  n = 163 n = 164
Mean duration of asthma, y 16.4 16.2
  n = 611 n = 622
  1. BID = twice-daily; MF-DPI = mometasone furoate administered via a dry powder inhaler; PAR = perennial allergic rhinitis; QD PM = once-daily in the evening; SAR = seasonal allergic rhinitis.